

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	OnabotulinumtoxinA
PRONUNCIATION	on" a bot u lin um tox in A
THERAPEUTIC CLAIM	Treatment of cervical dystonia, severe primary axillary hyperhidrosis, Glabellar lines, blepharospasm, strabismus

CHEMICAL NAMES

- Protein (Clostridium botulinum strain Allergan-Hall-A gene ntnh), compd. with 451-1296-botulin A (Clostridium botulinum strain Allergan-Hall-A gene bont precursor) (454'→430")-disulfide with 1-438-botulin A (Clostridium botulinum strain Allergan-Hall-A gene bont precursor), compd. with 203-626-hemagglutinin HA70 (Clostridium botulinum strain Allergan-Hall-A gene ha70), compd. with hemagglutinin HA34 (Clostridium botulinum strain Allergan-Hall-A gene ha34), compd. with 1-202-hemagglutinin HA70 (Clostridium botulinum strain Allergan-Hall-A gene ha70), compd. with hemagglutinin HA17 (Clostridium botulinum strain Allergan-Hall-A gene ha17)
- Clostridium botulinum* Type A-1 neurotoxin complex (Allergan strain-900 kDa)

STRUCTURAL FORMULA

Light chain

PFVVKQFNKY	DPVNGVDIAY	IKIPNAGQMQ	PVKAFKIHNK	IWVIPERDTF
TNPEEGDLNP	PPEAKQVPVS	YYDSTYLSTD	NEKDNYLKGV	TKLFERIYST
DLGRMLLTSI	VRGIPFWGGS	TIDTELKVID	TNCINVIQPD	GSYRSEELNL
VIIGPSADII	QFECKSFGHE	VLNLTRNGYG	STQYIRFSPD	FTFGFEESLE
VDTNPLLGAG	KFATDPAVTL	AHELIIHAGHR	LYGIAINPNR	VFKVNTNAYY
EMSGLEVSFE	ELRTFGGHDA	KFIDSLQENE	FRLYYYNKFK	DIASLTNKKAK
SIVGTTASLQ	YMKNVFKEKY	LLSEDTSGKF	SVDKCLKFDKL	YKMLTEIYTE
DNFVKFFKVL	NRKTYLNFDK	AVFKINIVPK	VNYTIYDGFN	LRNTNLAANF
NGQNTTEINNM	NFTKLNFTG	LFEFYKLLCV	RGIITSK	

Heavy chain

				ALN
DLCIKVNNWD	LFFSPSEDNF	TNDLNKGEEI	TSDTNIEAAE	ENISLDLIQQ
YYLTFNFDNE	PENISIENLS	SDIIGQLELM	PNIERFPNGK	KYELDKYTMF
HYLRAQEFEH	GKSRIALTNS	VNEALLNPSR	VYTFSSDYV	KKVNKATEAA
MFLGWVEQLV	YDFTDETSEV	STTDKIADIT	IIIPYIGPAL	NIGNMLYKDD
FVGALIFSGA	VILLEFIPEI	AIPVLGTFAL	VSYIANKVLT	VQTIDNALS
RNEKWDEVYK	YIVTNWLAKV	NTQIDLIRKK	MKEALENQAE	ATKAIINYQY
NQYTEEEKNN	INFNIDLSS	KLNESINKAM	ININKFLNQC	SVSYLMNSMI
PYGVKRLDF	DASLKDALLK	YIYDNRGTLI	GQVDRLKDKV	NNTLSTDIPF
QLSKYVDNQR	LLSTFTEYIK	NIINTSILNL	RYESNHLIDL	SRYASKINIG
SKVNFDPIDK	NQIQLFNLES	SKIEVILKNA	IVYNSMYENF	STSFWIRIPK
YFNSISLNNE	YTIINCMENN	SGWKVSLNYG	EIIWTLQDTQ	EIKQRVVFYK
SQMINISDYI	NRWIFVTITN	NRLNNSKIYI	NGRLIDQKPI	SNLGNIHASN

NIMFKLDGCR	DTHRYIWIKY	FNLFDKELNE	KEIKDLYDNQ	SNSGILKDFW
GDYLQYDKPY	YMLNLYDPNK	YVDVNNVGIR	GYMYLKGPRG	SVMTTNIYLN
SSLYRGTKFI	IKKYASGNKD	NIVRNNDRVY	INVVVKNKEY	RLATNASQAG
VEKILSALEI	PDVGNLSQVV	VMKSKNDQGI	TNKCKMNLQD	NNGNDIGFIG
FHQFNNAKL	VASNWYNRQI	ERSSRTLGCS	WEFIPVDDGW	GERPL

Disulfide bridges location

429-453 1234-1279

MOLECULAR WEIGHT

900 kDa

TRADEMARK

BOTOX[®]/BOTOX[®] Cosmetic

MANUFACTURER

Allergan

CAS REGISTRY NUMBER

1309378-01-5

NOTES:

- 1) This statement supersedes N07;59.
- 2) The name *onaclostox* is hereby rescinded; the new USAN is *onabotulinumtoxinA*.